Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized study
✍ Scribed by Enzo Galligioni; Michele Quaia; Alberto Merlo; Antonino Carbone; Antonella Spada; Daniela Favaro; Manuela Santarosa; Cosimo Sacco; Renato Talamini; the Gruppo Oncologico Clinico Cooperativo del Nord-Est
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 613 KB
- Volume
- 77
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
Active specific immunotherapy (ASI) is a strategy that attempts to boost the host's immune response specifically against its own tumor. The purpose of this study was to investigate the effect of adjuvant AS1 in patients with renal carcinoma.
METHODS.
Of 120 consecutive patients, 60 were randomized to a control group and 60 to receive AS1 comprised of 3 intradermal injections of lo7 autologous irradiated tumor cells mixed with lo7 Bacillus Calmette-Guerin (in the first 2 vaccinations) or alone. At randomization and 1, 6, and 12 months after completing immunotherapy, the treated patients were evaluated for the development of delayed type cutaneous hypersensitivity (DTCH) response to autologous tumor and autologous normal renal cells.